Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

DOAC therapy prevents VTE recurrence, bleeding in patients with cancer

30 Sep 2018

Use of direct-acting oral anticoagulants (DOACs) in patients with cancer and venous thromboembolism (VTE) results in only two episodes of clinically significant bleeding and no episodes of recurrent VTE, according to the results of a single-centre, retrospective, observational study.

Of the 37 patients included, 12 were diagnosed with pulmonary embolism (PE), 21 with deep vein thrombosis (DVT), three with both DVT and PE, and one with DVT and superficial vein thrombosis. The most commonly used DOAC was apixaban (n=27).

None of the patients had a recurrent DVT or PE at 6 months. In addition, only two patients experienced adverse effects during treatment.

A previous study involving patients with active cancer and VTE showed rivaroxaban to have similar efficacy compared to enoxaparin and a vitamin K antagonist for the prevention of VTE recurrence and the reduction of major bleeding events. A head-to-head comparison of rivaroxaban with long-term low-molecular-weight heparin is needed in cancer patients. [Lancet Haematol 2014;1:e37-46]

To assess the use of DOAC in patients with cancer and VTE, the present study identified patients by a retrospective data extraction of those treated at Ochsner Medical Centre from 1 January 2013 through 31 December 2015.

Eligibility criteria for the review included age ≥18 years, a confirmed diagnosis of VTE and active or history of cancer, and treatment with dabigatran, apixaban, rivaroxaban or edoxaban for at least 6 months. The primary endpoints were the rate of VTE recurrence and incidence of bleeding at 6 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.